Hereditary Angioedema Therapeutic Market Poised for Double-Digit Growth at 16.79% CAGR to Reach US$ 14.19 Billion by 2029

Maximize Market Research unveils a comprehensive study on the Hereditary Angioedema Therapeutic Market. The market is expected to reach US$ 14.19 billion by 2029, propelled by a significant Compound Annual Growth Rate (CAGR) of 16.79%.

Get PDF sample report: 

Market Overview

Hereditary Angioedema (HAE) is a rare genetic disorder characterized by swelling in various body parts. The Hereditary Angioedema Therapeutic Market addresses this condition by providing treatment options. Rising awareness, increasing diagnosis rates, and the introduction of innovative therapies are anticipated to drive substantial growth in this market.

Market Dynamics

Several key factors are fueling the Hereditary Angioedema Therapeutic Market:

  • Growing Awareness and Diagnosis: Heightened awareness among both patients and healthcare professionals is leading to earlier HAE detection, consequently increasing the demand for treatment options.
  • Unmet Medical Needs: Current treatment approaches may not be effective for all patients, creating a gap in the market that can be addressed by the development of more targeted and efficacious therapies.
  • Technological Advancements: Research and development advancements in areas like gene therapy and RNA interference hold promise for long-term disease management, further accelerating market expansion.

Market Segmentation

The Hereditary Angioedema Therapeutic Market is segmented by Drug Class, Treatment Type, and Route of Administration:

  • Drug Class: C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, and Others
  • Treatment Type: Prophylaxis (preventative) and On-demand (episodic treatment)
  • Route of Administration: Intravenous, Subcutaneous, and Oral

Market Players

The report identifies leading participants in the Hereditary Angioedema Therapeutic Market, including BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Pharming Group N.V., CSL Limited, Shire Plc, Attune Pharmaceuticals, Adverum Biotechnologies, KalVista Pharmaceuticals, along with established pharmaceutical companies like Novartis, Sanofi, and Takeda.

Competitive Landscape

The report offers a deep dive into the competitive landscape, highlighting factors such as mergers and acquisitions, geographical expansion strategies, and research & development initiatives undertaken by key players to gain a competitive edge.

Impact of COVID-19

The report acknowledges the impact of the COVID-19 pandemic on the Hereditary Angioedema Therapeutic Market. It explores potential disruptions in clinical trials, supply chains, and patient treatment protocols due to the pandemic. However, the report also emphasizes the potential for increased adoption of telehealth consultations and remote patient monitoring to ensure treatment continuity during such disruptions.

Availability of the Report

This press release provides a brief overview of the Hereditary Angioedema Therapeutic Market. The Maximize Market Research report offers a detailed analysis of the market, including market size and growth forecasts, market segmentation, and competitive landscape insights.

Tables and data about the " Hereditary Angioedema Therapeutic Market " can be found in a comprehensive research study and an in-depth TOC: 


Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

Email: [email protected]

Phone No.: +91 96071 95908, +91 9607365656


More Related Reports:

Global NaS Battery Market 

Educational Toy Market 

Gas Meters Market